Roll over image to magnify


  • Availability:In Stock

Formular: Omeprazole 20mg


- Short-term treatment of active duodenal ulcer (Mepraz should not be used as maintenance therapy for treatment of patients with duodenal ulcer disease)

- Gastric ulcer

- Gastroesophageal Reflux Disease (GERD):

  • Short term treatment (4-8 weeks) of severe erosive esophagitis (grade 2 or above) which has been diagnosed by endoscopy.
  • Short term treatment (4-8 weeks) of symptomatic gastroesophageal reflux disease (esophagitis) poorly responsive to customary medical treatment, usually including an adequate course of a histamine H2-receptor antagonist.

- Long term treatment of pathological hypersecretory conditions (Zollinger-Ellison syndrome, multiple endocrine adenomas)

Dosage and Administrations:

  •  Short-term treatment of active duodenal ulce: The recommended adult oral dose is 20mg once daily. Most patients heal within 4 weeks. Some patients may required an additional 4 weeks pf therapy.
  • Gastric ulcer: 20mg once daily for 4-8 weeks
  • Severe erosive esophagitis or poorly responsive gastroesophageal reflux disease: The recommended adult oral dose is 20mg daily for 4-8 weeks.
  • Pathological hypersecretory conditions: The recommended adult oral dose is 60mg once daily


  • Hypersensitivity to any component(s) of the drug
  • Mepraz should not be used in pregnant women.

Adverse reactions: Mepraz is well tolerated. Its adverse reactions occur rarely: nause, headache, diarrhea, constipation, flatulence and skin rashes.


  • Symptomatic responses to mepraz therapy does not preclude presence of gastric malignancy diseases
  • The breast-feeding of infants should be discontinoued in mothers receiving Mepraz.



Bình luận Facebook